[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Worowski, 1968 - Google Patents

The hypercoagulability in mercury chloride intoxicated dogs

Worowski, 1968

Document ID
8693629507256325344
Author
Worowski K
Publication year
Publication venue
Thrombosis and Haemostasis

External Links

Snippet

Experimental acute mercury chloride intoxication has been produced in the dog by subcutaneous injection of HgCl 2 in a daily dose of 3 mg/kg of weight for 3 days. The following features of hypercoagulability of dog blood have been found: increase of …
Continue reading at www.thieme-connect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood

Similar Documents

Publication Publication Date Title
Kumada et al. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals
Despotis et al. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques
Loew et al. Dose-dependent influence of acetylsalicylic acid on platelet functions and plasmatic coagulation factors
Okajima et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
Mombelli et al. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction.
Taylor Jr et al. A model for thrombin protection against endotoxin
JPS58500994A (en) Pharmaceutical composition for hemostasis
Thachil et al. Current concepts in the management of disseminated intravascular coagulation
Wall et al. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides
Lorand et al. Assay method for the “fibrin-stabilizing factor.”
Levine et al. The effect of platelet factor 4 (PF4) on assays of plasma heparin
Giles et al. Studies of factors V and VIII: C in an animal model of disseminated intravascular coagulation.
Ogawa et al. A comparative study of prothrombin complex concentrates and freshfrozen plasma for warfarin reversal under static and flow conditions
Flight et al. Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents
Monteagudo et al. Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
Egberg et al. Platelet aggregation induced by ADP and thrombin in Reptilase defibrinated dogs
Krajewski et al. Real-time measurement of free thrombin: evaluation of the usability of a new thrombin assay for coagulation monitoring during extracorporeal circulation
EP0535129B1 (en) An anticoagulant preparation
Worowski The hypercoagulability in mercury chloride intoxicated dogs
Aritomi et al. Evidence that the Protein C Activation Pathway Amplifies the lnhibition of Thrombin Generation by Recombinant Human Thrombomodulin in Plasma
Ueyama et al. Progressing ischemic stroke in a homozygote with variant antithrombin III.
Flute Coagulation and fibrinolysis after injury
Raivio et al. Monitoring high-dose heparinization during cardiopulmonary bypass–A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays
Matthiasson et al. Study of the interaction of dextran and enoxaparin on haemostasis in humans
Bauer et al. Congenital antithrombin III deficiency: insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation